Remedy’s new boss says the Control studio will ‘double down’ on what makes it unique

It’s a big year for Remedy Entertainment. Last year was marred by the ill-fated launch of the multiplayer shooter FBC: Firebreak, which was so disastrous it led to former CEO Tero Virtala stepping down from his position. Now, with the much-anticipated sequel Control Resonant slated for later in 2026, the studio’s new boss Jean-Charles Gaudechon — who took over in March — is offering some reassuring words about where Remedy is headed.

Here’s what Gaudechon had to say in a statement as part of Remedy’s most recent business review:

The gaming industry and market have always been dynamic, now more volatile than ever. As the industry searches for its footing, Remedy will double down on what makes the studio unique: our creative identity, memorable IPs, and commitment to delivering exceptional quality and originality.

We are more focused than ever on moving forward with franchise expansion, self-publishing, and commercial discipline to improve our business performance. The studio is in good shape to deliver on these pillars.

Firebreak was a misstep that attempted to merge Remedy’s beloved storytelling and worldbuilding with a co-op shooter. But, despite being known for taking creative risks, Remedy is a relatively conservative company, and spent the years leading up to Firebreak’s launch building itself up so that it could 1) own the majority of its own properties; and 2) develop multiple projects simultaneously. And this seems to have helped insulate the studio from any significant negative impacts from Firebreak’s failure, despite the fact that live-service disasters are currently ravaging the rest of the industry.

In addition to Resonant — which the CEO reaffirmed is on track for a 2026 release — Remedy is also developing a pair of Max Payne remakes that are being published by Rockstar, and the studio is currently in the “proof of concept” phase on an unannounced title. And it seems that any future projects will likely be much more in line with what the studio is known for.

“Remedy’s DNA is a product of an ambitious creative culture that has been carefully built over three decades,” Gaudechon said. “Protecting and reinforcing that culture and letting it compound is ultimately how we create value and is a key priority for me as the CEO.”